Aradigm Corporation Share Price

ARDMQ

US0385054004

Biotechnology & Medical Research

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Valuation : Aradigm Corporation

Market Cap	4.89M 4.21M 3.95M 3.6M 6.79M 467M 6.81M 46.83M 18.27M 236M 18.34M 17.94M 782M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.03M 10.34M 9.44M 17.78M 1.22B 17.84M 123M 47.86M 617M 48.05M 47.01M 2.05B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news : Aradigm Corporation

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
27/04/20	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
08/04/20	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
30/03/20	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
30/03/20	Motion for Asset Sale Approved for Aradigm Corporation	CI
09/03/20	Bidding Procedure Approved for Aradigm Corporation	CI
21/02/20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20/02/20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
06/11/19	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
30/10/19	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
21/10/19	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19/07/19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

More news

Press Releases : Aradigm Corporation

15/06/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/06/20	ARADIGM CORP : Other Events (form 8-K)	AQ
30/04/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/04/20	ARADIGM CORP : Other Events (form 8-K)	AQ
06/04/20	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	+6.73%	-	-	702K
LONZA GROUP AG	-0.78%	-1.42%	+2.49%	+22.78%	50.47B
REVOLUTION MEDICINES, INC.	-6.00%	-0.75%	+442.41%	+544.39%	44.56B
IQVIA HOLDINGS INC.	-0.24%	+0.74%	+38.69%	+18.02%	43.08B
BEONE MEDICINES AG	-1.55%	-2.07%	+23.08%	+81.47%	41.7B
CELLTRION, INC.	-0.31%	-0.83%	+16.15%	+51.42%	33.21B
MEDPACE HOLDINGS, INC.	-1.79%	-3.24%	+27.00%	+129.56%	16.77B
ASCENDIS PHARMA A/S	-0.58%	-2.12%	-	-	16.28B
EUROFINS SCIENTIFIC SE	-0.88%	-0.66%	+11.60%	+27.75%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	-1.25%	+78.59%	+46.66%	13.92B
Average	-1.38%	-0.28%	+80.00%	+115.26%	27.46B
Weighted average by Cap.	-1.70%	-1.06%	+95.71%	+133.63%

See all sector performances

Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
ARDMQ Stock

As early as today, start finding the best investment opportunities!

	2016	2017
Net sales	195K 168K 158K 144K 271K 18.64M 272K 1.87M 729K 9.41M 732K 716K 31.19M	14.46M 12.46M 11.69M 10.67M 20.1M 1.38B 20.16M 139M 54.1M 698M 54.31M 53.13M 2.31B
Net income	-32.94M -28.38M -26.61M -24.29M -45.76M -3.15B -45.91M -316M -123M -1.59B -124M -121M -5.27B	-10.7M -9.22M -8.65M -7.9M -14.87M -1.02B -14.92M -103M -40.04M -516M -40.19M -39.32M -1.71B
Net Debt	-9.37M -8.08M -7.57M -6.91M -13.02M -896M -13.06M -89.83M -35.05M -452M -35.19M -34.42M -1.5B	7.91M 6.82M 6.39M 5.84M 10.99M 756M 11.03M 75.85M 29.59M 382M 29.71M 29.06M 1.27B

Aradigm Corporation Share Price

Stocks

ARDMQ

US0385054004

Biotechnology & Medical Research

Valuation : Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases : Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile